CO-MORBIDITY OF CARDIOVASCULAR DISEASES AND RHEUMATOID ARTHRITIS

  • PANDYA DT Department of Pharmaceutics and Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Anand, Gujarat, India. http://orcid.org/0000-0002-7485-6392
  • Patel Gc Department of Pharmaceutics and Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Anand, Gujarat, India.
  • Ambegaokar Pp Department of Pharmaceutics and Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Anand, Gujarat, India.
  • Vyas Nd Department of Pharmaceutics and Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Anand, Gujarat, India.

Abstract

Rheumatoid Arthritis (RA) is a chronic disease related to swelling of joints which leads to restriction in movement due to pain and deformity in mainly in feet, ankle, wrist and fingers. It is an autoimmune disease and the manifestations caused due to its occurrence are not clearly understood. In today’s time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular abnormalities, several infections, certain mental disorders and malignancies. Among which cardiovascular comorbid diseases are the most common kind relating to disorders of heart and blood vessel that eventually leads to severe conditions like angina, myocardial infarction (MI), stroke, rheumatic heart disease and many more. RA affects the quality of life of patients directly or indirectly but it mainly shows a significant increase in the prevalence of cardiovascular diseases. Hence, it is essential to diagnose and understand about the related manifestations when one is suffering from Rheumatoid Arthritis. These studies will aid to make better treatment and management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both the diseases and related risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the prevention and treatment of these conditions.

Keywords: Cardiovascular diseases, Comorbidity, Rheumatoid arthritis, Inflammation.

References

1. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case control analysis. Arthritis and Rheumatism 2008; 58: 2612-2621.

2. Christina Charles- Schoeman, “Cardiovascular disease and Rheumatoid Arthritis: An Update” Current Rheumatology Reports 2012; 14 (5): 455-462.

3. Shanthi Mendis, PekkaPuska, Bo Norrving. Global Atlas on Cardiovascular Disease Prevention and Control 2011; 3–18.

4. Lancet. Global, regional and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990- 2013: a systematic analysis for the Global Burden of Disease Study 2013, 2015; 385: 89-200.

5. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis and Rheumatism 2005; 52 (2) : 402–411.

6. Anne Kerola, Epidemiology of co morbidities in early rheumatoid arthritis with emphasis on cardiovascular disease, the Faculty of Medicine of the University of Helsinki; Helsinki 2015.

7. Desai SS, Myles JD, Kaplan MJ. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012;14:R270.

8. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690–7.

9. Anne Kerola, epidemiology of co morbidities in early rheumatoid arthritis with emphasis on cardiovascular disease, the faculty of medicine of the university of Helsinki; Helsinki 2015.

10. Annals of the rheumatic diseases-bmj journals

11. arthritis.org, Arthritis Foundation-“Arthritis and Heart Disease-Treatment of co morbidity”

12. Avina-Zubieta JA, Choi HK. Risk of Cardiovascular mortality in patients with rheumatoid arthritis: a Meta analysis of observational studies. Arthritis Rheum 2008.

13. K. Hamamoto, S. Yamada, M. Yasumoto, M. Yoda, K. Yoda, A. Tsuda, K. Okamoto, H. Goto, and M. Inaba Am. J Hypertens. 2016; 29(3):340-347.

14. WebMD Corporation Launches Print Magazine," The Write News, April 22, 2005.

15. Handout on Health: Rheumatoid Arthritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. August 2014. Retrieved July 2, 2015) NIH PUBLICATION NO. 14-4179

16. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Critical Care Medicine 2006, 34 (7): 1874–82.

17. Okunieff P, Xu J, Hu D, Liu W, Zhang L, Morrow G, Pentland A, Ryan JL, Ding I. Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int. J Radiat Oncol Biol Phys 2006; 65 (3): 890–8.

18. Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, Aydin S. Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med a Physiol Pathol Clin Med 2006; 53 (1): 49–54.

19. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. J Phymed 2003; 12 (6–7): 445-52.

20. Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and independent immunomodulatory effects. J Biol Chem 2006; 281 (20): 14192–206.

21. Masimocugno, fransecaingegnoli, Roberta gualtirrotti, flaviofatini. Current Vascular Pharmacology 2016; 6 (1875-6212).

22. Health guideline: http://www.healthline.org [Last accessed on 2016 Nov 08].

23. Schillinger M, Exner M, Mlekusch W. Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation 2005; 111(17): 2203–2209.

24. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis & Rheumatism 2005; 52(3): 722–32.

25. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis & Rheumatism 2004; 50(11): 3444–9.

26. Svenson KL, Pollare T, Lithell H, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism1988; 37(2):125–130.

27. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24): 2957–63.

28. Hurlimann D, Forster A, Noll G. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106(17): 2184–7.

29. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthritis & Rheumatism 2005; 52(8): 2293–9.

30. Gonzalez-Gay MA, Gonzalez- Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1219–23.

31. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7(3): R634–43.

32. Rho YH, Chung CP, Oeser A. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis & Rheumatism 2009, 61(11): 1580–5.

33. Roman MJ, Devereux RB, Schwartz JE. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46(1): 194–9.

34. Maradit-Kremers H, Nicola PJ, Crowson CS. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66(1): 76–80.

35. Xie JJ, Wang J, Tang TT. The Th17/Treg functional imbalance during atherogenesis in ApoE(−/−) mice. Cytokine 2009.

36. van Es T, van Puijvelde GH, Ramos OH. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388 (2): 261–5.

37. Liang J, Zheng Z, Wang M. Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res 2009; 37(3): 862–6.

38. Eid RE, Rao DA, Zhou J. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells; Circulation 2009,119(10): 1424–32.

39. Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 2009; 87(3): 212–8.

40. Taleb S, Romain M, Ramkhelawon B. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206(10): 2067–77.

41. Anne Grete Semb. Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis. 39-49.

42. Maud N Vissers, John JP Kastelein, Erik S Stroes. Evidence-based Management of Lipid Disorders 2010; 25-38.

43. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25(4): 241–5.

44. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196(2): 756–63.

45. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37(5): 486–94.

46. Mattey DL, Thomson W, Ollier WE, Batley M, Davies PG, Gough AK. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of follow-up from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56(5): 1408–16.

47. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM. Association of interleukin-6 (IL-6)-174 G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204(1): 178–83.

48. Vallvé JC, Paredes S, Girona J, Uliaque K, Ribalta J, Hurt-Camejo E. Tumor necrosis factor-alpha −1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. J Rheumatol 2008; 35(9): 1697–703.

49. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis, Arthritis Rheum 1997; 40(6): 1106–14.

50. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52(3): 722–32.

51. Mariana J. Kaplan Mariana J. Kaplan. Cardiovascular complications of Rheumatoid Arthritis - Assessment, prevention and treatment. Rheum Dis Clin North Am 2010; 36(2): 405–426.

52. Marc Feldmann. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-371.

53. D. Golan, A.H. Tashjian , E. J. Armstrong and A. W Armstrong. An excerpt from the excellent “Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy”. Arthritis and rheumatism 2006; 54(11): 3452-3464.

54. Inhuman experiment blog spot official website: http://www.inhumanexperiment.blogspot.in

55. Adalimumab information website: https://medlineplus.gov/druginfo/meds/a603010.html

56. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. Oxford University Press 2001; 2nd edition.

57. Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States. 2001-2005. Arthritis Care Res (Hoboken) 2010; 62(4): 460-4.

58. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62(6):1576-82.

59. Crowson CS, Matteson EL, Myasoedova E. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63(3): 633-9.

60. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011; 7(7): 399-408.

61. Wasko MC. Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol 2004; 16(2): 109-13.

62. Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol 2011; 30 (Suppl 1): S3-8.

63. Solomon DH, Reed G, Kremer JM. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015.

64. Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27(2): 283-303.

65. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002; 64(1): 52-60.

66. Minor MA, Brown JD. Exercise maintenance of persons with arthritis after participation in a class experience. Health Educ Q. 1993; 20(1): 83-95.

67. Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2007; 66(9): 1195-1201.

68. Soderlin M K, Hakala M, Nieminen P. Anxiety and depression in a community-based rheumatoid arthritis population. Scand J Rheumatol.2000; 29(3): 177-83.
Statistics
447 Views | 473 Downloads
Citatons
How to Cite
PANDYA DT, P. Gc, A. Pp, and V. Nd. “CO-MORBIDITY OF CARDIOVASCULAR DISEASES AND RHEUMATOID ARTHRITIS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 5, May 2017, pp. 72-77, doi:10.22159/ajpcr.2017.v10i5.16078.
Section
Review Article(s)